Abdakibart's Phase 3 in hidradenitis suppurativa tests whether Phase 2 HiSCR75 efficacy replicates at registrational scale in a crowding competitive field

Bull

A positive outcome would see abdakibart achieve statistical significance on the primary HiSCR75 endpoint at Phase 3 scale, ideally with response rates approximating or exceeding the Phase 2 LOTUS results, while maintaining a clean safety profile consistent with the monthly dosing regimen. This would position abdakibart as a differentiated IL-1α/β dual inhibitor with a competitive efficacy and convenience profile, substantially de-risking the regulatory path and validating the $405M financing commitment.

Bear

The most likely failure mode is a regression to the mean at larger scale — the Phase 2 absolute response rates, while numerically impressive, were generated in a relatively small trial (~250 patients) and may not hold in a broader, more heterogeneous Phase 3 population. Secondary failure modes include an unfavorable safety signal emerging with longer exposure, or statistical significance being achieved only at the higher dose with a narrower therapeutic window, complicating label negotiations and commercial differentiation.